PRN2246: BTK Inhibitor
Multiple Sclerosis

Phase 1 dosing completed

  • Bruton’s tyrosine kinase (BTK) is a key element in the B cell signaling pathway
  • B cells are key drivers in MS, regulating autoimmunity and neuro-inflammatory responses
  • Distinct from other BTK inhibitors, PRN2246 readily permeates the blood-brain barrier (BBB)
  • The action of PRN2246 on both sides of the BBB offers broad activity, compared to other agents in the treatment of MS, to target systemic autoimmunity and local central nervous system (CNS) inflammation

‚Äč

  • Dosing has been completed for all participants in a Phase 1 clinical trial of PRN2246
  • Sanofi plans to develop this experimental oral therapy for the treatment of MS and, potentially, other CNS diseases that are driven by autoantibodies and inflammation